Catalog No.
Product Name
Application
Product Information
Citations
-
immunopotentiator
Inosine pranobex is a potent, broad-spectrum antiviral compound for HIV infection. Inosine pranobex is an immunopotentiator. -
IL-1 inhibitor
IX 207-887 is a novel antiarthritic agent which inhibits the release of interleukin-1 (IL-1). - Gamma-glutamylcysteine (TFA) ((γ-glutamylcysteine (TFA)), an intermediate in glutathione (GSH) synthesis, is a dipeptide served as an essential cofactor for the antioxidant enzyme glutathione peroxidase (GPx).
-
IL-12/IL-23 inhibitor
Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively. -
Rab27a-JFC1 Inhibitor
Nexinhib20 is a selective inhibitor of the Rab27a-JFC1 interaction (IC50: 2.6 μM) and Rac-1-GTP signaling. This compound effectively inhibits neutrophil exocytosis, adhesion, and β2 integrin activation, demonstrating significant anti-inflammatory properties. Nexinhib20 is suitable for research applications focused on systemic inflammation and myocardial ischemia-reperfusion injury. -
Endogenous Metabolite
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice. -
PDE Inhibitor
Theophylline, a potent phosphodiesterase (PDE) inhibitor, primarily targets PDE3, leading to relaxation of airway smooth muscle and enhanced bronchodilation. This compound also functions as an adenosine receptor antagonist and exhibits anti-inflammatory properties by elevating IL-10 levels and inhibiting NF-κB translocation into the nucleus. Additionally, Theophylline has been shown to induce apoptosis in certain cell types. Its applications are particularly relevant in the research of asthma and chronic obstructive pulmonary disease (COPD). -
AMPK Agonist
10-Gingerol is an AMPK agonist derived from ginger oleoresin, exhibiting notable anti-inflammatory, antioxidant, and anti-proliferative properties. It effectively suppresses neointimal hyperplasia and inhibits the proliferation of vascular smooth muscle cells. Demonstrating significant radical scavenging activities, 10-Gingerol has IC50 values of 10.47 μM against DPPH, 1.68 μM against superoxide, and 1.35 μM against hydroxyl radicals. This compound also inhibits MDA-MB-231 tumor cell line proliferation with an IC50 of 12.1 μM, while targeting the PI3K/Akt signaling pathway to suppress proliferation, migration, invasion, and promote apoptosis. It holds potential for research applications in ulcerative colitis. -
TNF Receptor Inhibitor
Muscone, a TNF receptor inhibitor, is derived from the traditional Chinese medicine musk. It effectively inhibits NF-κB signaling and NLRP3 inflammasome activation, resulting in a significant reduction of inflammatory cytokines such as IL-1β, TNF-α, and IL-6. This compound is valuable in research focused on inflammation, cardiac function restoration, and improving survival rates in various pathological conditions. -
Anti-Inflammatory/Antibacterial Agent
(20R)-Protopanaxadiol acts as an anti-inflammatory and antibacterial agent, derived from ginsenosides. It effectively exhibits anti-inflammatory properties while maintaining a lack of significant cytotoxicity against tumor cell lines. Additionally, (20R)-Protopanaxadiol has been shown to inhibit the uptake of 2-deoxy-D-glucose (2-DG), making it relevant for research applications focusing on metabolic pathways and the modulation of inflammatory processes. -
IL-1 Inhibitor
Diacerein is a potent IL-1 inhibitor that functions by reducing the production of IL-1 converting enzyme, thereby inhibiting the activation of IL-1β and its downstream signaling pathways. This compound exhibits significant anti-inflammatory and anti-rheumatic properties, making it useful for various research applications, including studies on osteoarthritis and the management of bronchospasm and airway inflammation in asthmatic models. Diacerein is recognized as a slow-acting drug for symptomatic relief of osteoarthritis, facilitating insights into long-term therapeutic strategies. -
Histamine H1 Receptor Antagonist
Epinastine is a selective histamine H1 receptor antagonist, known for its effectiveness as a mast cell stabilizer. It exhibits high affinity for neuronal octopamine receptors in various insects, demonstrating potential roles in modulating immune responses. Epinastine also inhibits pro-inflammatory cytokines such as TARC, IL-8, and IL-4, making it valuable for research into allergic diseases and anti-cancer immunity mechanisms. Its ability to reduce scratching behavior and vascular permeability further underscores its relevance in studying allergic and inflammatory conditions. -
IL-1β Converting Enzyme Inhibitor
SDZ 224-015 is a potent inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1, demonstrating significant inhibitory activity. This compound exhibits anti-COVID-19 properties through its interaction with the main protease (Mpro), with an IC50 value of 30 nM. SDZ 224-015 is suitable for research applications focusing on inflammation, cytokine signaling, and viral pathogenesis. -
IL-23 receptor antagonist
Icotrokinra (JNJ-77242113) is an orally available and selective antagonist of the interleukin-23 (IL-23) receptor. It potently inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀ = 5.6 pM) and suppresses IL-23-induced interferon-γ (IFN-γ) production in natural killer (NK) cells (IC₅₀ = 18.4 pM). Icotrokinra also demonstrates anti-inflammatory activity in a rat TNBS-induced colitis model. It is a promising therapeutic candidate for the study and treatment of inflammatory conditions such as psoriasis, psoriatic arthritis, and inflammatory bowel disease (IBD). -
IL-1R antagonist
Raleukin (AMG-719) is a recombinant, non-glycosylated human interleukin-1 receptor (IL-1R) antagonist. It functions by competitively inhibiting the binding of interleukin-1 (IL-1) to its receptor, thereby blocking IL-1–mediated pro-inflammatory signaling. As one of the first biological agents developed to inhibit IL-1 activity, Raleukin has potential applications in the treatment of inflammatory and autoimmune diseases. -
IL-6 inhibitor
LMT-28 is an orally active and the first synthetic interleukin-6 (IL-6) inhibitor that acts by directly binding to gp130, a key signal-transducing component of the IL-6 receptor complex. It selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130, exhibiting low toxicity. LMT-28 is a promising compound for research into IL-6-mediated inflammatory and autoimmune diseases. - 6-Demethoxytangeretin is a flavonoid compound isolated from *Citrus reticulata* with demonstrated anti-inflammatory and anti-allergic properties. It inhibits IL-6 production and the expression of related genes in human mast cells by modulating the ALK and MAPK signaling pathways. Additionally, 6-Demethoxytangeretin enhances CRE-mediated transcription in hippocampal neurons, indicating potential neuroregulatory effects.
-
PPAR agonist
Lobeglitazone is a novel thiazolidinedione-class compound and an orally active dual agonist of peroxisome proliferator-activated receptors (PPARs), with EC₅₀ values of 137.4 nM for PPARγ and 546.3 nM for PPARα. In addition to its metabolic effects, Lobeglitazone functions as an inhibitor of multiple pro-inflammatory and pro-fibrotic signaling pathways, including ERK, JNK, Smad, and NF-κB. Lobeglitazone exhibits a broad range of pharmacological activities, including anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic effects. These properties make it a promising candidate for therapeutic research in metabolic syndrome, type 2 diabetes, cardiovascular disease, and fibrosis-related conditions. - Anti-inflammatory agent 35 (compound 5a27) is an orally active curcumin analogue that exhibits potent anti-inflammatory activity. It exerts its effects by blocking mitogen-activated protein kinase (MAPK) signaling and inhibiting the nuclear translocation of the NF-κB subunit p65, thereby suppressing key inflammatory pathways. Additionally, compound 5a27 reduces neutrophil infiltration and the production of pro-inflammatory cytokines. In vivo, it significantly attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI), highlighting its potential as a therapeutic candidate for inflammatory and respiratory disorders.
- Lysophosphatidylcholines (LPCs) are orally active lysolipids and key components of oxidized low-density lipoprotein (oxLDL). They are bioactive molecules known to induce cellular injury, promote the production of pro-inflammatory cytokines such as interleukin-1β (IL-1β), and trigger apoptosis. LPCs play a significant role in the pathophysiology of various inflammatory conditions and have been implicated in the progression of sepsis by amplifying inflammatory responses. Due to these properties, LPCs are actively studied in the context of inflammation, cardiovascular disease, and sepsis-related research.
-
TNFα/IL-2 Inhibitor
Immuno modulator-1 is a potent inhibitor of TNFα and IL-2, displaying IC50 values of 4.7 nM and 26 nM, respectively, in human peripheral blood mononuclear cells (hPBMC). This compound is valuable for investigating immune response modulation and inflammatory pathways. Additionally, Immuno modulator-1 demonstrates a hERG potassium channel blocking effect, exhibiting a 20% inhibitory percentage at a concentration of 3 μM, making it relevant for studies involving cardiac safety profiles. -
IL-13 Inhibitor
IL13Rα2 D1 is a potent inhibitor of the IL-13/IL13Rα2 signaling pathway. It effectively suppresses IL-13-induced cellular processes, including adhesion, migration, invasion, and proliferation. Additionally, IL13Rα2 D1 inhibits the phosphorylation of key signaling proteins such as FAK, Src, AKT, and ERK1/2, as well as the expression of matrix metalloproteinases (MMPs). This compound is valuable for research focused on cancer biology, particularly in the context of colorectal cancer. -
NO、TNF-α、IL-12 Inhibitor
(R)-5,7-Dimethoxyflavanone acts as an inhibitor of nitric oxide (NO), tumor necrosis factor-alpha (TNF-α), and interleukin-12 (IL-12), demonstrating significant anti-inflammatory properties. In biological assays, this compound exhibits potent antimutagenic activity, effectively reducing MeIQ-induced mutagenesis in the Ames test using S. typhimurium strains TA100 and TA98. Its capacity to modulate inflammatory mediators makes it a valuable tool in research focused on inflammation and mutagenesis. -
Anti-IL-1β Antibody
Abdakibart is a humanized IgG4 monoclonal antibody that selectively targets IL-1β, a key cytokine involved in the inflammatory response. This reagent is particularly valuable for research applications related to inflammatory diseases, including type 2 diabetes. By inhibiting IL-1β, Abdakibart can help elucidate the pathways involved in inflammation and contribute to the development of novel therapeutic strategies. -
IL-17A Modulator
IL-17A modulator-3 is a selective modulator targeting IL-17A. This compound demonstrates effective inhibition of the IL-17A/A receptor complex with an IC50 value of less than 10 μM. It is suitable for research applications related to inflammation, cancer biology, and autoimmune disorders, providing valuable insights into these critical areas of study. -
Anti-IL-1β Antibody
SSGJ-613 is a fully human monoclonal antibody that targets interleukin-1 beta (IL-1β). This reagent is designed for the investigation of inflammatory conditions, particularly gouty arthritis, by inhibiting the activity of IL-1β, a key mediator in the inflammatory response. Its application extends to research focused on understanding the role of IL-1β in various diseases and therapeutic development. -
IL-17 modulator
IL-17 modulator 6 is a potent inhibitor of Interleukin 17 (IL-17) with a pIC50 of 9.1. This compound effectively modulates IL-17 signaling and is utilized in the study of inflammatory and autoimmune diseases. Researchers may employ IL-17 modulator 6 to explore therapeutic strategies targeting IL-17 pathways. -
IL-2 Fusion Protein
Lecomkafusp alfa is an IL-2 fusion protein designed to enhance immunomodulatory activity. It consists of human IL-2 linked via a protease-cleavable peptide to a humanized single-domain VHH fragment that targets albumin. This compound demonstrates significant antineoplastic properties, making it a valuable tool in cancer immunotherapy research and the exploration of novel therapeutic strategies. -
Anti-IL-17A Antibody
HB-0017 is a humanized IgG1κ monoclonal antibody that specifically targets interleukin-17A (IL-17A). This antibody effectively inhibits IL-6 secretion induced by IL-17A with an IC50 value of 2.09 nM. HB-0017 has demonstrated significant efficacy in reducing ear thickness in a psoriasis-like mouse model induced by Imiquimod, as well as alleviating inflammation in models of IL-17A-induced arthritis and air pouch inflammation. -
Anti-IL-17A Antibody
Velvakiment is a humanized VHH nanobody that specifically targets interleukin-17A (IL-17A). This antibody is valuable for investigating autoimmune diseases, including multiple sclerosis and rheumatoid arthritis, by elucidating the role of IL-17A in inflammatory pathways. Its specificity and affinity facilitate advanced research on therapeutic interventions aimed at modulating IL-17A activity in various disease contexts. -
Anti-IL-17RB Antibody
Ponumkibart is a humanized IgG4κ antibody specifically designed to target the interleukin-17 receptor B (IL-17RB). This antibody serves as a critical tool for investigating the role of IL-17 signaling in various pathologies, including autoimmune diseases and inflammatory conditions. Its application in research includes the study of immune response modulation and the development of therapeutic strategies targeting IL-17 pathways. -
Anti-IL-13 Antibody
Zumilokibart is a humanized IgG1κ antibody that specifically targets interleukin-13 (IL-13). This antibody is designed to inhibit the biological activity of IL-13, a cytokine implicated in various allergic and inflammatory diseases. It is suitable for research applications focused on asthma, allergic rhinitis, and other conditions where IL-13 plays a pivotal role in pathophysiology. -
IL-17 Modulator
IL-17 Modulator 5 is a potent inhibitor targeting interleukin-17 (IL-17) with an IC50 of 1 nM. This compound exhibits significant inhibition of IL-17 associated pathways, playing a critical role in inflammatory responses. It is applicable in research on autoimmune diseases and inflammatory disorders, facilitating investigations into therapeutic avenues for conditions such as psoriasis and rheumatoid arthritis. -
IL-2/IL-2Rα Antagonist
Ro26-4550 TFA is a low micromolar antagonist of the interleukin-2 (IL-2) and IL-2 receptor alpha (IL-2Rα) interaction, exhibiting an IC50 value of 3 μM. This compound serves as a valuable tool for investigating the IL-2 signaling pathway, making it relevant for studies in immunology and cancer research. Its ability to inhibit IL-2 signaling can aid in the understanding of immune responses and the development of therapeutic strategies targeting IL-2 mediated pathways. -
IL-10 Fusion Protein
Vimekofusp is a recombinant IL-10 fusion protein that specifically targets IL10RA and IL10RB receptors. This agent exhibits potent immunomodulatory activity by enhancing anti-inflammatory responses and promoting regulatory T cell functions. It is primarily utilized in research applications focusing on autoimmune diseases, chronic inflammation, and therapeutic strategies aimed at modulating the immune system. -
IL-2 Fusion Protein
Efpixileukin alfa is a fusion protein consisting of a human IL-2 variant connected at the C-terminus to a human immunoglobulin G1 (IgG1) Fc fragment. This immunomodulator enhances T-cell proliferation and activation, making it valuable for therapeutic applications in cancer immunotherapy and autoimmune diseases. Research involving Efpixileukin alfa focuses on its potential to improve immune responses and its role in modulating the tumor microenvironment. -
IL-23 Inhibitor
IL-23 cyclic peptide inhibitor 105 targets the interleukin-23 (IL-23) pathway, serving as a specific inhibitor of this pro-inflammatory cytokine. It exhibits significant potential in modulating inflammatory responses associated with disorders such as inflammatory bowel disease (IBD). This compound is a valuable tool for researchers investigating the role of IL-23 in various inflammatory conditions and developing therapeutic strategies targeting IL-23 signaling. -
IL-17 Modulator
IL-17 Modulator 1 is a small molecule that selectively targets the IL-17 signaling pathway. This compound exhibits high efficacy in modulating IL-17 activity, making it valuable for studying inflammatory diseases. It is particularly relevant in research focusing on psoriasis, ankylosing spondylitis, and psoriatic arthritis, providing insights into mechanisms of disease prevention and treatment. -
IL-17 Inhibitor
IL-17-IN-4 is a potent IL-17 inhibitor with an IC50 of less than 0.1 μM, making it a valuable tool for investigating the role of IL-17 in inflammatory diseases. This compound can facilitate research aimed at understanding the mechanisms of inflammation and the therapeutic potential of IL-17 modulation in conditions such as rheumatoid arthritis and psoriasis. Its high potency enables effective studies of IL-17 signaling pathways in various biological contexts. -
IL-17 Modulator
IL-17 modulator 8 is an orally active modulator targeting interleukin-17 (IL-17). This compound significantly reduces pro-inflammatory cytokines such as IL-6 and IFN-γ, as well as edema. IL-17 modulator 8 is applicable in research focused on arthritis and related inflammatory diseases. -
IL-2/IL-2Rα Binding Antagonis
Ro26-4550 is a potent antagonist of IL-2/IL-2Rα binding, exhibiting an IC50 value of 3 μM. This compound is valuable for investigating the modulation of IL-2 signaling pathways, which play a critical role in T cell proliferation and immune response regulation. Research applications include studying autoimmune diseases, cancer immunotherapy, and potential therapeutic interventions targeting IL-2-mediated effects. -
IL-1β Secretion Inhibitor
K-832 is an orally active inhibitor of IL-1β secretion, targeting the interleukin-1 pathway. This compound demonstrates significant biological activity by reducing inflammatory responses associated with autoimmune disorders. K-832 is applicable in the research of rheumatoid arthritis and other conditions linked to elevated IL-1β levels, making it a valuable tool for studying inflammation and immune response modulation. -
IL-17 Modulator
IL-17 Modulator 9 is an orally active inhibitor targeting the IL-17 pathway. This compound significantly reduces levels of pro-inflammatory cytokines such as IL-6 and IFN-γ while also diminishing edema. It serves as a valuable tool for studying various inflammatory conditions and exploring therapeutic interventions. -
Anti-IL-1βAntibody
Anflekitug is a CHO-expressed human antibody that specifically targets interleukin-1 beta (IL-1β). This monoclonal antibody features a huIgG1 heavy chain and a huκ light chain, exhibiting a predicted molecular weight of 145 kDa. Anflekitug is suitable for applications in inflammatory research, including studies of autoimmune diseases and cytokine signaling pathways. For isotype control experiments, human IgG1 kappa may be used as an appropriate reference. -
IL-17 Modulator
IL-17 modulator 10 is a potent inhibitor of the IL-17 signaling pathway, demonstrating an IC50 of 0.71 μM in HTRF assays that evaluate the binding of IL-17A to IL-17RA. This compound is particularly relevant for research focused on autoimmune and inflammatory diseases, providing valuable insights into therapeutic interventions targeting IL-17-mediated pathways. -
IL-17 Modulator
IL-17 Modulator 2 is an orally active compound that targets the IL-17 pathway. It is effective in significantly reducing levels of pro-inflammatory cytokines, including IL-6 and IFN-γ, while also decreasing edema. This reagent is suited for research applications related to arthritis and other inflammatory conditions. -
IL-1 Inhibitor
E5090 is an orally active inhibitor of IL-1 generation, acting through its conversion in vivo to the active deacetylated form, DA-E5090. This compound exhibits significant anti-inflammatory properties, making it valuable for studies related to inflammation and immune response modulation. E5090 is useful in various immunology research applications, particularly in understanding the role of IL-1 in disease states. -
IL-17A Inhibitor
Acetyl zingerone is an IL-17A inhibitor that exhibits potent anti-inflammatory and antioxidant activities. This compound plays a crucial role in protecting melanocytes from DNA damage by inhibiting matrix metalloproteinases and downregulating IL-17A target gene expression. Acetyl zingerone is valuable for research focused on inflammatory skin conditions and mechanisms of cellular protection. -
IL-1/β-transferase Inhibitor
Pentenocin B is an IL-1/β-transferase inhibitor that selectively targets the interleukin-1 signaling pathway. This compound exhibits weak inhibitory activity against IL-1 and β-transferase, which are crucial in mediating inflammatory responses. Pentenocin B is useful for research applications focused on inflammation and related signaling mechanisms.
